查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1819900

2025-2033年荷爾蒙避孕市場報告（依產品（口服避孕藥、子宮內避孕器、注射避孕藥、陰道環等）、荷爾蒙、年齡層、最終使用者和地區分類）

Hormonal Contraceptive Market Report by Product (Oral Contraceptive Pills, Intrauterine Device, Injectable Birth Control, Vaginal Rings, and Others), Hormone, Age Group, End User, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 142 Pages | 商品交期: 2-3個工作天內

價格

2024年，全球荷爾蒙避孕市場規模達194億美元。展望未來， IMARC Group預計到2033年，該市場規模將達到268億美元，2025-2033年期間的複合年成長率（CAGR）為3.48%。受全球生殖健康和計劃生育意識的提升、婦女賦權（尤其是在發展中地區）的增強以及全球範圍內避孕藥具接受度和使用率的不斷提高的推動，該市場正在穩步成長。

荷爾蒙避孕市場分析：

  • 主要市場促進因素：全球範圍內對計劃生育的要求和接受度推動了荷爾蒙避孕藥的需求。各國政府和非政府組織致力於降低意外懷孕率，這推動了該市場的成長。
  • 主要市場趨勢：根據荷爾蒙避孕市場預測，最近對該市場產生重大影響的趨勢是長效可逆避孕藥（包括子宮內避孕器和植入物）的消費量不斷增加，因為它們更有效、作用時間更長。
  • 地理趨勢：北美和西歐由於較高的認知度、收入水平和醫療設施，在荷爾蒙避孕藥的使用方面處於領先地位。相反，由於城市化、醫療支出和生活方式等因素，預計亞太地區將成長最快。
  • 競爭格局：根據荷爾蒙避孕藥市場研究，荷爾蒙避孕藥市場擁有多家大型製藥公司，擁有廣泛的產品組合和分銷網路。無論大小公司都在增加研發預算，以開發副作用最小且方便消費者使用的新藥。
  • 挑戰與機會：雖然各個地理區域存在的文化阻力和監管障礙制約了市場成長，但仍有投資個人化避孕解決方案和關注女性就業增加的尚未解決的新興市場的多個機會。

荷爾蒙避孕市場趨勢：

提高全球對生殖健康的認知與教育

荷爾蒙避孕藥在全球的廣泛使用很大程度上取決於生殖健康意識和教育的提高。各國政府和世界衛生組織等相關國際組織不斷推廣透過安全有效的避孕措施進行計劃生育的理念和優勢。根據世界衛生組織統計，2021年全球育齡婦女數為19億，其中11億需要計劃生育。其中，8.74億人正在使用現代避孕方法，1.64億女性的避孕需求尚未滿足。因此，這極大地影響了荷爾蒙避孕藥市場的收入。具體而言，全球範圍內開展了廣泛的宣傳活動，面向男性和女性，告知他們控制懷孕的能力以及減少人口快速成長的有效方法。此外，也推出了許多針對青少年和年輕人的教育項目，為他們日後做出明智的計劃生育決策奠定基礎。這些教育措施只有在獲得醫療保健服務和諮詢的同時，才能有效發揮作用，使人們能夠區分不同的荷爾蒙避孕方法。在這方面，全面的全球教育和健康計畫對於確保這些產品在不同地區普及至關重要。

技術進步與產品創新

新型、更優的荷爾蒙避孕方案的開發徹底改變了這個領域，也推動了荷爾蒙避孕市場價值的提升。最近，一種新型超低劑量製劑（20 μg EE 和 3 mg DRSP）已上市，可24小時/4小時服用（Yaz；拜耳公司）。其療效與舊式口服避孕藥（COC）相似，甚至更佳，且出血情況可接受。此外，藥物傳輸系統的開發正在帶來更可靠、更易於管理且副作用更少的產品。延長週期避孕藥和子宮內避孕器的改進（例如，更少的健康危害和更長的使用時間）都滿足了消費者日益成長的便利性和生活方式兼容性的需求。此外，這些進步提升了消費者的體驗和依從性，從而擴大了市場，因為女性更有可能使用和恢復避孕措施。此外，避孕產品技術的創新利用消費者的興趣、採用和市場選擇，推出了更精良的技術。因此，這為荷爾蒙避孕藥市場創造了積極的前景。

計劃生育政策措施和資金

政府推出的支持性政策和增加計劃生育計畫資金等政策促進了荷爾蒙避孕藥市場的成長。一些地區，尤其是發展中國家的政府，已訂定政策，確保個人能夠獲得避孕藥具，並將其作為公共衛生和婦女賦權措施的一部分。這些政策降低了避孕藥具的成本，使生殖健康服務更加全面，惠及所有人，並將避孕教育納入公共衛生運動。此外，全球聯盟和機構提供資金，幫助服務匱乏的地區獲得生殖健康服務。所有這些措施都旨在降低成本，並鼓勵人們使用避孕藥。確保人們能夠輕鬆低價獲得荷爾蒙避孕藥的政策有助於滿足公共衛生需求和其他社會經濟目標。

荷爾蒙避孕市場區隔：

按產品分類：

  • 口服避孕藥
  • 子宮內避孕器（IUD）
  • 注射避孕藥
  • 陰道環
  • 其他

口服避孕藥佔據了荷爾蒙避孕藥市場的大部分佔有率

口服避孕藥 (OCP) 憑藉其無與倫比的功效、便利性和易得性，繼續引領荷爾蒙避孕市場，成為最大的產品細分市場。荷爾蒙避孕市場概況表明，由於其安全性，避孕藥是全球最常見的避孕方法，能夠確保可預測且可靠的計劃生育。除了可靠性之外，這類產品的市場也因配方的多樣性而呈現多樣化，有複方製劑和純黃體素製劑可供選擇，這反映了醫生和消費者的偏好。此外，市場趨勢取決於 OCP 與其他長期荷爾蒙結合避孕藥相比的價格，以及基於 OCP 長期使用歷史的記錄便利性，儘管存在副作用，但 OCP 仍然是安全的。同時，該細分市場仍在不斷發展，許多新的選擇已經並將繼續被開發，以減少副作用並提高荷爾蒙製劑的安全性和舒適度。整體而言，避孕OCP仍是全球女性生殖健康的前提。

荷爾蒙分手：

  • 僅含黃體素的避孕藥
  • 合併荷爾蒙避孕藥

複合激素避孕藥佔據產業最大佔有率

荷爾蒙類子市場以複方荷爾蒙避孕藥 (CHC) 為主。此細分市場高佔有率的主要原因在於其極高的避孕功效和顯著的健康益處。其益處包括：保證月經週期的持續時間和經期的舒緩，預防卵巢囊腫，以及顯著降低子宮內膜癌的風險。 CHC 有藥丸、陰道環和貼片等形式，為使用者提供了更方便的給藥方式選擇。因此，CHC 因其高度的靈活性和額外的健康益處，對廣大用戶來說是一個相當吸引人的選擇。一些臨床醫生提到了一些擔憂，例如情緒障礙的風險和體重增加的可能性。然而，CHC 的持續改進旨在降低這些副作用的風險，從而提高用戶滿意度和依從性。

按年齡層分類：

  • 15-24歲
  • 25-34歲
  • 35-44歲
  • 44歲以上

15-24 歲代表領先的細分市場

根據已確定的人口分佈趨勢和社會特徵，15-24歲年齡層是荷爾蒙避孕藥具使用者中最大的群體。這一年齡層通常指青春期晚期和成年早期，在這段時期，人們最積極地探索和利用避孕措施，並將其作為性健康和生殖健康管理的一部分。此外，青少年和年輕人性行為的增多，以及廣泛的安全性行為教育計畫（旨在倡導安全性行為並避免意外懷孕）的開展，也推動了這一年齡層的顯著成長。因此，這也對荷爾蒙避孕藥市場的統計數據產生了正面影響。教育機構、醫療保健提供者和社區組織特別關注這一年齡段，進行各種推廣活動和諮詢，使人們更容易獲得有關不同避孕方法的資訊。同樣，在組建家庭之前發展事業或完成學業的願望也促使這些年輕人尋求充足、安全、可靠的避孕措施，這極大地促進了這一細分市場的強勁成長。

按最終用戶分類：

  • 醫院和診所
  • 居家護理
  • 門診手術中心
  • 其他

家庭護理在市場上佔據明顯主導地位

荷爾蒙避孕市場的主要終端使用者是家庭護理領域，這得益於其提供的便利性和隱私性。鑑於當前消費者要求在家中舒適地做出醫療保健決策的趨勢，對可自行管理的產品的需求必然會成長。避孕藥具比以往任何時候都更容易取得，這進一步促進了這一趨勢。例如，口服避孕藥、透皮貼片和陰道環現在可以無需他人幫助地使用，並且在世界大部分地區都很容易買到。根據荷爾蒙避孕市場分析，許多線上平台和遠距醫療服務使這些產品的取得變得簡單，增強了在家中管理避孕需求的吸引力。此外，家庭照護趨勢與以消費者為中心的醫療保健的整體發展相呼應，個人在滿足自身健康需求方面尋求最佳的便利性、保密性和自主性。這些因素顯著改變了荷爾蒙避孕市場的動態。

按地區分類：

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

北美引領市場，佔據最大的荷爾蒙避孕市場佔有率

該報告還對所有主要區域市場進行了全面分析，包括北美（美國和加拿大）；亞太地區（中國、日本、印度、韓國、澳洲、印尼等）；歐洲（德國、法國、英國、義大利、西班牙、俄羅斯等）；拉丁美洲（巴西、墨西哥等）；以及中東和非洲。報告指出，北美是荷爾蒙避孕藥最大的區域市場。

從地理上看，北美是全球領先的荷爾蒙避孕藥市場，這得益於該地區完善的醫療基礎設施、對避孕措施的高度認知以及政府的大力支持。此外，北美還有幾家領先的製藥公司正在投資開發更便利、有效和安全的避孕藥。同時，美國人擁有最發達的健康文化，他們更傾向於提前「吞服」口服避孕藥，而不是子宮內避孕環。此外，許多類型的避孕藥都包含在保險範圍內，包括政策性保險，這提高了可及性。公共和私人組織提供的眾多教育計畫也宣傳了使用避孕藥的好處。這種全面的支持確保了北美不僅是一個龐大的市場，而且是全球荷爾蒙避孕領域的領先地區。

競爭格局：

市場研究報告還對市場競爭格局進行了全面分析，並提供了所有主要公司的詳細資料。荷爾蒙避孕產業的一些主要市場參與者包括：

  • Afaxys公司
  • Agile Therapeutics公司
  • 艾爾建公司（AbbVie Inc.）
  • 拜耳公司
  • 西普拉有限公司
  • 強生公司
  • 默克公司
  • 輝瑞公司
  • 皮拉馬爾集團
  • 梯瓦製藥工業股份有限公司

荷爾蒙避孕藥市場的主要參與者致力於資助研究，並提升其產品的功效和安全性。他們不斷減少副作用，提高用戶便利性，以獲得市場認可並保持品質領先地位。此外，包括拜耳公司、輝瑞公司和默克在內的公司希望透過在發展中國家的收購和聯盟來擴大其全球影響力，因為這些國家目前對荷爾蒙避孕藥的需求較高。此外，製造商經常推廣荷爾蒙避孕藥，並向更多女性宣傳其相關優勢。這些進展支持發展目標，同時也有助於實現更全面的公共衛生政策目標。

本報告回答的關鍵問題：

  • 全球荷爾蒙避孕市場迄今表現如何，未來幾年將如何表現？
  • 全球荷爾蒙避孕市場的促進因素、限制因素和機會是什麼？
  • 每個促進因素、限制因素和機會對全球荷爾蒙避孕市場有何影響？
  • 主要的區域市場有哪些？
  • 哪些國家代表最具吸引力的荷爾蒙避孕市場？
  • 根據產品，市場是如何分類的？
  • 荷爾蒙避孕市場上最具吸引力的產品是什麼？
  • 基於荷爾蒙的市場區隔是怎樣的？
  • 荷爾蒙避孕藥市場上最吸引人的荷爾蒙是什麼？
  • 根據年齡層，市場是如何分類的？
  • 荷爾蒙避孕市場上哪個年齡層的人最有吸引力？
  • 根據最終用戶，市場是如何分類的？
  • 荷爾蒙避孕市場上最有吸引力的最終用戶是誰？
  • 市場的競爭結構是怎麼樣的？
  • 全球荷爾蒙避孕市場的主要參與者/公司有哪些？

本報告回答的關鍵問題：

  • 全球荷爾蒙避孕市場迄今表現如何，未來幾年將如何表現？
  • 全球荷爾蒙避孕市場的促進因素、限制因素和機會是什麼？
  • 每個促進因素、限制因素和機會對全球荷爾蒙避孕市場有何影響？
  • 主要的區域市場有哪些？
  • 哪些國家代表最具吸引力的荷爾蒙避孕市場？
  • 根據產品，市場是如何分類的？
  • 荷爾蒙避孕市場上最具吸引力的產品是什麼？
  • 基於荷爾蒙的市場區隔是怎樣的？
  • 荷爾蒙避孕藥市場上最吸引人的荷爾蒙是什麼？
  • 根據年齡層，市場是如何分類的？
  • 荷爾蒙避孕市場上哪個年齡層的人最有吸引力？
  • 根據最終用戶，市場是如何分類的？
  • 荷爾蒙避孕市場上最有吸引力的最終用戶是誰？
  • 市場的競爭結構是怎麼樣的？
  • 全球荷爾蒙避孕市場的主要參與者/公司有哪些？

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 二手資料
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

第5章：全球荷爾蒙避孕市場

  • 市場概況
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依產品

  • 口服避孕藥
  • 子宮內避孕器（IUD）
  • 注射避孕藥
  • 陰道環
  • 其他

第7章：市場分化：荷爾蒙

  • 僅含黃體素的避孕藥
  • 合併荷爾蒙避孕藥

第8章：市場區隔：依年齡段

  • 15-24歲
  • 25-34歲
  • 35-44歲
  • 44歲以上

第9章：市場區隔：依最終用戶

  • 醫院和診所
  • 居家護理
  • 門診手術中心
  • 其他

第10章：市場細分：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第 11 章：SWOT 分析

第 12 章：價值鏈分析

第 13 章：波特五力分析

第 14 章：價格分析

第 15 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Afaxys Inc.
    • Agile Therapeutics Inc.
    • Allergan Inc. (AbbVie Inc.)
    • Bayer AG
    • Cipla Limited
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Piramal Group
    • Teva Pharmaceutical Industries Ltd
Product Code: SR112025A4403

The global hormonal contraceptive market size reached USD 19.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 26.8 Billion by 2033, exhibiting a growth rate (CAGR) of 3.48% during 2025-2033. The market is experiencing steady growth driven by global awareness of reproductive health and family planning, the rising empowerment of women, particularly in developing regions, and the growing acceptance and use of contraceptives across the globe.

Hormonal Contraceptive Market Analysis:

  • Major Market Drivers: The demand for hormonal contraceptives is driven by family planning requirements and acceptance across the globe. The various governments and non-governmental organizations that solely try to reduce the rate of unplanned pregnancies are leading to the growth of this market.
  • Key Market Trends: According to the hormonal contraceptive market forecast, the recent trend that will have a major impact on this market is the increasing consumption of long-acting reversible contraceptives including IUDs and implants on account of being more effective and longer action period.
  • Geographical Trends: North America and Western Europe majorly lead in hormonal contraceptive usage due to high awareness levels, income, and healthcare facilities. On the contrary, Asia Pacific is anticipated to grow fastest due to urbanization, healthcare expenditure, and lifestyle factors.
  • Competitive Landscape: According to the hormonal contraceptive market research, the hormonal contraceptives market has several big pharmaceutical companies with extensive product portfolios and distribution networks. Both small and large companies are increasing their budgetary allocation to research and development (R&D) activities to develop new drugs with minimal side effects while maintaining consumer convenience.
  • Challenges and Opportunities: While the existence of cultural resistance and regulatory hurdles in various geographical areas constrain market growth, there remain multiple opportunities to invest in personalized contraceptive solutions and focus on unaddressed emerging markets with an increase in female employment.

Hormonal Contraceptive Market Trends:

Increasing global awareness and education on reproductive health

The extensive utilization of hormonal contraceptives on a global scale is largely dependent on increased awareness and education about reproductive health. Governments and relevant international organizations, such as the World Health Organization, continuously promote the concept and advantages of family planning through safe and effective contraceptive use. According to the World Health Organization, there were 1.9 billion women of reproductive age worldwide in 2021, 1.1 billion of whom need family planning. Of these, 874 million are using modern contraceptive methods, and there are 164 million women with an unmet need for contraception. Thus, this is significantly influencing the hormonal contraceptive market revenue. Specifically, extensive global campaigns target both women and men, informing them about their ability to control pregnancies and effective ways to reduce rapid population growth. Moreover, numerous educational programs targeting teens and young individuals have been rolled out to lay the groundwork for well-informed family planning decisions later in life. These educational initiatives are only effective when complemented by access to healthcare services and consultations that enable individuals to differentiate among various hormonal contraceptive methods. In this regard, comprehensive global educational and health programs are indispensable in ensuring these products are taken up in different regions.

Technological advancements and product innovation

The development of new and better hormonal contraceptive options that revolutionize the area also propels hormonal contraceptive market value. Recently, a novel ultra-low-dose preparation of 20 μg EE and 3 mg DRSP has been marketed in a 24/4 regimen (Yaz; Bayer AG). The efficacy is similar to, if not better than, older COCs, and the bleeding pattern is acceptable. Additionally, drug delivery system development is resulting in more reliable items that are simpler to manage and produce fewer side effects. Extended-cycle pills and improvements to intrauterine devices, such as fewer health hazards and a longer period of utilization, respectively, all address the increasing need for consumer convenience and lifestyle compatibility. In addition, such advancements enhance the consumer experience and compliance, resulting in an expanded market since women are more likely to use and resume contraceptive use. In addition, innovations in contraceptive product technologies take advantage of consumers' acquired interest and adoption and market choice to introduce more refined technologies. Therefore, this is creating a positive hormonal contraceptive market outlook.

Policy initiatives and funding for family planning

Policies, such as supportive government policies and increased funding for family planning programs, facilitate the hormonal contraceptive market growth. Several governments in various regions, particularly in developing countries, have passed policies to ensure that individuals have access to contraceptives as part of public health and women's empowerment measures. These policies lower the cost of contraceptives, make reproductive health services comprehensive and available to everyone, and incorporate contraceptive education in public health campaigns. Furthermore, global consortia and institutions offer funding to help underserved areas access reproductive health services. All these measures seek to reduce the cost and convince individuals to get contraceptives. Policies that guarantee easy and low-priced access to hormonal contraceptives help to meet public health needs and other socio-economic targets.

Hormonal Contraceptive Market Segmentation:

Breakup by Product:

  • Oral Contraceptive Pills
  • Intrauterine Device (IUD)
  • Injectable Birth Control
  • Vaginal Rings
  • Others

Oral contraceptive pills account for the majority of the hormonal contraceptive market share

Oral contraceptive pills (OCPs) continue to lead the hormonal contraceptive market as the largest product segment due to their unmatched combination of efficacy, convenience, and availability. The hormonal contraceptive market overview suggests that pills are the most common contraceptive method worldwide due to their safety, which secures predictable and reliable family planning. In addition to their reliability, the market for these products is diversified by the variability of formulations, with pills available in combined and progestin-only versions that reflect medical and consumer preferences. Moreover, the market tendency is determined by the price of OCPs in comparison with other long-term hormone-conjugated contraceptives, and the ease of documentation based on the long history of using OCPs that, despite the side effects, remain safe. In confluence with this, the segment is still developing, and many new options have been and continue to be developed to reduce the side effects and enhance the safety and comfort of hormonal formulations. Overall, contraceptive OCPs remain the premise of reproductive health for women worldwide.

Breakup by Hormone:

  • Progestin-only Contraceptive
  • Combined Hormonal Contraceptive

Combined hormonal contraceptive holds the largest share of the industry

The hormone sub-segment is dominated by combined hormonal contraceptives (CHCs). The main factor contributing to the segment's high share is their very high contraceptive efficacy combined with significant health benefits. Among the beneficial effects, it is worth mentioning the guaranteed duration of the menstrual cycle and the severity of menstruation, the prevention of ovarian cysts, and the significant reduction in the risk of endometrial cancer. CHCs are available in the form of pills, vaginal rings, and patches, giving users an additional choice of the form of administration that is most convenient for them. Thus, CHCs are an attractive option for a wide range of users due to their great flexibility and additional health benefits. Among the concerns, some clinicians mention the risk of mood disorders and the likelihood of weight gain. However, ongoing improvements aim to decrease the risk of these side effects, enhancing user satisfaction and adherence.

Breakup by Age Group:

  • 15-24 Years
  • 25-34 Years
  • 35-44 Years
  • Above 44 Years

15-24 years represents the leading market segment

The group of 15-24 years stands out as the largest segment of hormonal contraceptive users, based on identified trends in demographic distribution and social peculiarities. This age range usually refers to late adolescence and young adulthood, a period when individuals are most active in exploring and utilizing contraceptive options as part of their sexual and reproductive health management routines. In addition, the segment's considerable growth is driven by increased sexual activity among adolescents and young individuals, supported by broad educational programs that teach safe sex and promote the avoidance of unplanned pregnancies. Thus, this is also positively influencing the hormonal contraceptive market statistics. Educational institutions, healthcare providers, and community organizations pay special attention to this age group, conducting various outreach activities and consultations to make information about different methods of contraception more accessible. Similarly, the desire to build a career or complete education before starting a family also encourages these young individuals to seek adequate, secure, and reliable contraceptive options, contributing significantly to the strong representation of this submarket.

Breakup by End User:

  • Hospitals and Clinics
  • Homecare
  • Ambulatory Surgical Centers
  • Others

Homecare exhibits a clear dominance in the market

The leading end-user in the hormonal contraceptive market is the homecare segment, driven by the convenience and privacy it offers. Given the current trend of consumers demanding to make their healthcare decisions from the comfort of their homes, the demand for products that can be self-administered was bound to increase. This trend is further facilitated by the fact that contraceptives have become more attainable than ever before. Oral pills, transdermal patches, and vaginal rings, for example, can now be utilized without anyone's help and are readily available on the market in most parts of the world. According to the hormonal contraceptive market analysis, many online platforms and telehealth services make access to these products easy, enhancing the appeal of managing contraceptive needs at home. Furthermore, the homecare trend corresponds to the overall developments in consumer-centered healthcare, whereby individuals are seeking optimal levels of convenience, confidentiality, and autonomy in attending to their health needs. These factors have significantly altered the dynamics within the hormonal contraceptive market.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest hormonal contraceptive market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for hormonal contraceptive.

Geographically, North America is the leading market for hormonal contraceptives globally due to the region's well-developed healthcare infrastructure, high awareness about contraceptive types, and strong government support. There are also several leading pharmaceutical companies in North America investing in the development of more convenient, effective, and safe contraceptives. At the same time, Americans are the most developed in terms of the culture of taking care of their health and they prefer to "swallow" an oral agent in advance rather than an intrauterine spiral. Additionally, many types of contraceptives are covered by insurance, including under policies, which enhance accessibility. Numerous educational programs provided by public and private organizations also inform about the benefits of using contraceptives. This comprehensive support ensures that North America is not only a large market but also a leading region in the global hormonal contraceptive space.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the hormonal contraceptive industry include:

  • Afaxys Inc.
  • Agile Therapeutics Inc.
  • Allergan Inc. (AbbVie Inc.)
  • Bayer AG
  • Cipla Limited
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Piramal Group
  • Teva Pharmaceutical Industries Ltd.

The major players in the hormonal contraceptive market are committed to funding research and enhancing the efficacy and safety of their products. They consistently reduce side effects and increase user convenience to gain market acceptance and keep quality leadership. Furthermore, firms including Bayer AG, Pfizer, and Merck & Co. want to extend their global footprint through acquisitions and alliances in developing countries, where the hormonal contraceptive demand is currently higher. Additionally, manufacturers frequently promote hormonal contraception and educate more women about the advantages associated. These developments support development goals while aiding more comprehensive public health policy goals.

Key Questions Answered in This Report:

  • How has the global hormonal contraceptive market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global hormonal contraceptive market?
  • What is the impact of each driver, restraint, and opportunity on the global hormonal contraceptive market?
  • What are the key regional markets?
  • Which countries represent the most attractive hormonal contraceptive market?
  • What is the breakup of the market based on the product?
  • Which is the most attractive product in the hormonal contraceptive market?
  • What is the breakup of the market based on the hormone?
  • Which is the most attractive hormone in the hormonal contraceptive market?
  • What is the breakup of the market based on the age group?
  • Which is the most attractive age group in the hormonal contraceptive market?
  • What is the breakup of the market based on the end user?
  • Which is the most attractive end user in the hormonal contraceptive market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global hormonal contraceptive market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hormonal Contraceptive Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Oral Contraceptive Pills
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Intrauterine Device (IUD)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Injectable Birth Control
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Vaginal Rings
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Hormone

  • 7.1 Progestin-only Contraceptive
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Combined Hormonal Contraceptive
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Age Group

  • 8.1 15-24 Years
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 25-34 Years
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 35-44 Years
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Above 44 Years
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Homecare
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Ambulatory Surgical Centers
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Afaxys Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Agile Therapeutics Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Allergan Inc. (AbbVie Inc.)
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Bayer AG
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Cipla Limited
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Johnson & Johnson
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Merck & Co. Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Pfizer Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Piramal Group
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
    • 15.3.10 Teva Pharmaceutical Industries Ltd
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Hormonal Contraceptive Market: Major Drivers and Challenges
  • Figure 2: Global: Hormonal Contraceptive Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Hormonal Contraceptive Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Hormonal Contraceptive Market: Breakup by Product (in %), 2024
  • Figure 5: Global: Hormonal Contraceptive Market: Breakup by Hormone (in %), 2024
  • Figure 6: Global: Hormonal Contraceptive Market: Breakup by Age Group (in %), 2024
  • Figure 7: Global: Hormonal Contraceptive Market: Breakup by End User (in %), 2024
  • Figure 8: Global: Hormonal Contraceptive Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Hormonal Contraceptive (Oral Contraceptive Pills) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Hormonal Contraceptive (Oral Contraceptive Pills) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Hormonal Contraceptive (Intrauterine Device-IUD) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Hormonal Contraceptive (Intrauterine Device-IUD) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Hormonal Contraceptive (Injectable Birth Control) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Hormonal Contraceptive (Injectable Birth Control) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Hormonal Contraceptive (Vaginal Rings) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Hormonal Contraceptive (Vaginal Rings) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Hormonal Contraceptive (Other Products) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Hormonal Contraceptive (Other Products) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Hormonal Contraceptive (Progestin-only Contraceptive) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Hormonal Contraceptive (Progestin-only Contraceptive) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Hormonal Contraceptive (Combined Hormonal Contraceptive) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Hormonal Contraceptive (Combined Hormonal Contraceptive) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Hormonal Contraceptive (15-24 Years) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Hormonal Contraceptive (15-24 Years) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Hormonal Contraceptive (25-34 Years) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Hormonal Contraceptive (25-34 Years) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Hormonal Contraceptive (35-44 Years) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Hormonal Contraceptive (35-44 Years) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Hormonal Contraceptive (Above 44 Years) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Hormonal Contraceptive (Above 44 Years) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Hormonal Contraceptive (Hospitals and Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Hormonal Contraceptive (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Hormonal Contraceptive (Homecare) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Hormonal Contraceptive (Homecare) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Hormonal Contraceptive (Ambulatory Surgical Centers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Hormonal Contraceptive (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Hormonal Contraceptive (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Hormonal Contraceptive (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: North America: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: North America: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: United States: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: United States: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Canada: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Canada: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Asia-Pacific: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Asia-Pacific: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: China: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: China: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Japan: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Japan: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: India: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: India: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: South Korea: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: South Korea: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Australia: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Australia: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Indonesia: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Indonesia: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Others: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Others: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Europe: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Europe: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Germany: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Germany: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: France: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: France: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: United Kingdom: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: United Kingdom: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Italy: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Italy: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Spain: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Spain: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Russia: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Russia: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Others: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Others: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Latin America: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Latin America: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Brazil: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Brazil: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Mexico: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Mexico: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Others: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Others: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Middle East and Africa: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Middle East and Africa: Hormonal Contraceptive Market: Breakup by Country (in %), 2024
  • Figure 87: Middle East and Africa: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 88: Global: Hormonal Contraceptive Industry: SWOT Analysis
  • Figure 89: Global: Hormonal Contraceptive Industry: Value Chain Analysis
  • Figure 90: Global: Hormonal Contraceptive Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hormonal Contraceptive Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Hormonal Contraceptive Market Forecast: Breakup by Product (in Million USD), 2025-2033
  • Table 3: Global: Hormonal Contraceptive Market Forecast: Breakup by Hormone (in Million USD), 2025-2033
  • Table 4: Global: Hormonal Contraceptive Market Forecast: Breakup by Age Group (in Million USD), 2025-2033
  • Table 5: Global: Hormonal Contraceptive Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 6: Global: Hormonal Contraceptive Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Hormonal Contraceptive Market: Competitive Structure
  • Table 8: Global: Hormonal Contraceptive Market: Key Players